DVHGF (Devonian Health Group) Risk Assessment

View and export this data going back to 2022. Start your Free Trial

What is Devonian Health Group Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Devonian Health Group is: High Risk: High uncertainty.

Competitive Comparison of Devonian Health Group's Risk Assessment

For the Biotechnology subindustry, Devonian Health Group's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Devonian Health Group's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Devonian Health Group's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Devonian Health Group's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Devonian Health Group (OTCPK:DVHGF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Devonian Health Group Risk Assessment Related Terms

Thank you for viewing the detailed overview of Devonian Health Group's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Devonian Health Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Devonian Health Group Inc (OTCPK:DVHGF) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

GSD:Canada

Address

360, Rue des Entrepreneurs, Montmagny, QC, CAN, G5V 4T1

Website

https://www.groupedevonian.com

Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.

Devonian Health Group Headlines

From GuruFocus

Devonian Announces the Closing of a $315,000 Private Placement and an Additional Loan of $500,000

By GlobeNewswire GlobeNewswire • 08-22-2019